bpc 157 ind status fda bpc-157 warning 2025 september The Hidden Risks of BPC‑157: What Patients Need to Know About Contamination and Safety FDA reviews regulatory status of

What payers require for Zepbound prior authorization Zepbound PA requirements are typically more stringent: Documented BMI of 30 or greater, or 27 or greater with at least one weight-related comorbidity Evidence of lifestyle intervention including documented participation in diet, exercise, and behavioral modification programs (usually for at least 3 to 6 months) Prior medication trials (some plans require documented failure of other weight management medications before approving tirzepatide) Specialist involvement (some plans require referral to or management by a bariatric medicine specialist, endocrinologist, or obesity medicine physician) Ongoing weight monitoring documentation with specific weight loss targets (typically 5% of baseline weight within 3 to 6 months of starting therapy) Patients researching BMI requirements for GLP-1 medications should understand that these thresholds directly correspond to the prior authorization criteria their provider must document

H., Reitz, R

and its P

Now heres the funny bit The MHRA in responding to our petition stated: Vitamin B12 could not legally be classified as a medicine that can be made available for sale without prescription in pharmacies because it is an injection and because the condition it is licensed to treat, pernicious anaemia, needs a clinician to diagnose it, and monitor its treatment (see point IV above)

Complete restriction typically becomes unnecessary as tissues regain baseline capacity